A US and EU perspective
By Daniele Severi Bruni & Sophie Schmitz
What’s the idea?
Payer concerns over increasing cost of therapies and uncertainty of clinical data has led to a growing interest in market access tools. These tools have many names and definitions, often referred to as innovative (IAA) or alternative access agreements (AAA). For the purpose of this review we will refer to them collectively as IAA. The agreements can be split into two key categories: finance based designed to reduce uncertainties over budget impact and cost; and outcome-based, designed to reduce clinician uncertainties over drug performance.
Please enter your details in the form on the right to download the full text
